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Tanya GK Bentley1, Antonino Catanzaro2 and Theodore G Ganiats3*Abstract
Background: With today’s rapid advances in technology and understanding of disease, more screening and
diagnostic tests have become available in a variety of sociodemographic and clinical settings. This analysis
quantifies the impact of varying prevalence rates on test performance for given sensitivity and specificity values.
Methods: Using a worked example of latent tuberculosis infection, we compared true-positive (TP) and
false-positive (FP) results when varying prevalence and test sensitivity and specificity. We used estimates from
published literature to estimate two tests’ sensitivity (81%, QuantiFERONW-TB Gold In-Tube; 88%, T-SPOTW.TB) and
specificity (99%; 88%), and we used World Health Organization data to estimate disease prevalence in five countries.
Results: Varying sensitivity impacted outcomes most in high-prevalence settings; change in specificity had greater
impact in low-prevalence settings. In switching from QuantiFERON-TB to T-SPOT.TB (higher sensitivity, lower
specificity), trade-offs between increasing case identification (TPs) and decreasing unnecessary treatments (FPs)
varied dramatically with prevalence. Lower-prevalence settings paid a greater “price” of more FPs for each TP
gained, with 37.7 FPs per TP in the United States (5% prevalence) versus 2.5 in the Ivory Coast (55% prevalence).
Conclusions: Prevalence affects test performance for given sensitivity and specificity values. To optimize test
performance, disease prevalence should be incorporated in testing decisions, and sensitivity and specificity should
be set locally, not globally. In lower-prevalence settings, using highly specific assays may optimize outcomes.
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With today’s rapid advances in technology and under-
standing of disease, more screening and diagnostic tests
have become available in a variety of sociodemographic
and clinical settings. Although these tests can be
described in various ways (such as use of receiver opera-
ting characteristic curves and predictive values), a pri-
mary factor is the number of true-positive, false-positive,
true-negative, and false-negative results that occur when
implementing a test. In addition to various environmen-
tal factors, these outcomes are determined in large part
by test sensitivity and specificity. For tests measured on a
continuous scale (e.g., blood glucose, valued in mmol/L)* Correspondence: tganiats@ucsd.edu
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reproduction in any medium, provided the orand dichotomized to “normal” or “abnormal,” sensitivity
and specificity are determined in large part by the posi-
tive test threshold: the test result that divides positively
defined results from those considered negative.
The relative impact of sensitivity and specificity on
true and false results and on disease outcomes is
described in Table 1. Although in reality these associa-
tions are rarely so direct because such tests are not typ-
ically used in isolation (e.g., further diagnosis or
confirmation of the condition often follows positive
results), we simplify here for the purposes of demonstra-
tion only. Sensitive tests are used to accurately identify
those with disease, and negative results from such tests
are used to rule out disease. Specific tests are used to
identify those without disease, and positive results are
used to rule in disease. Highly sensitive tests therefore
help detect disease and, in the case of infection, possiblyLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Potential outcomes of screening tests with varying levels of sensitivity and specificity
Test characteristic High sensitivity High specificity
Impact on results " True positives " True negatives
Testing goal Identify people with disease Identify people without disease
Treatment goal • Treat disease • Avoid unnecessary treatment
• Prevent future illness and, in the case of infection, possible disease
spread
Potential harms of opposite test
characteristic
Low sensitivity: Low specificity:
• " False negatives • " False positives
• " Potential future illness and suffering • " Bodily harms, toxicity, and financial
costs of unnecessary treatment
• " Potential future spread of disease (in the case of infection) • " Social stigmatization
• # confidence in screening program
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tests, on the other hand, help prevent unnecessary treat-
ments, toxicities, and costs among individuals not
infected with disease.
A given test’s sensitivity and specificity are negatively
associated: increasing sensitivity by changing the positive
test threshold results in a decreased specificity, and vice
versa. In this way, the selection of a positive test threshold
involves an inherent balancing act. For example, increas-
ing test sensitivity results in decreased specificity and
leads to more true- and false-positive results. Increasing
test specificity results in decreased sensitivity and leads to
fewer true- and false-positive results. Thus, in seeking the
sensitivity-specificity balance when determining the posi-
tive test threshold, a key question for clinicians and pol-
icymakers is how many false positives they are willing to
tolerate in order to get one additional true positive.Figure 1 Total TB prevalence per 100,000 populations by country, 20The magnitude of this trade-off between true and false
positives, the relative effects of sensitivity and specificity,
and, thus, decisions regarding optimal thresholds are
determined by multiple factors [1,2]. For example, there
are local considerations of capacity, staffing, and cli-
nician and technician skill; comorbidities, including im-
munosuppression; clinician and patient preferences;
disease characteristics; and variations in health
resources. In addition to these factors, disease preva-
lence plays a significant role.
We propose that disease prevalence must be consi-
dered in conjunction with other disease- and setting-
specific factors when setting a test’s positive result
threshold and when deciding between tests. Specifically,
decisions made in low-prevalence settings must not be
automatically extrapolated to settings with high disease
prevalence.07. Source: World Health Organization Global TB Database [4].
Table 2 True-positive resultsa in settings of varying
prevalence and tests of varying sensitivity
Disease prevalence rate Number of true-positive results
Sensitivity
50% 60% 70% 80%
20% 100 120 140 160
40% 200 240 280 320
60% 300 360 420 480
80% 400 480 560 640
a Predicted numbers based on a hypothetical population of 1,000 tested
individuals.
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varying prevalence and is thus well demonstrated with
tuberculosis (TB). TB is a common airborne disease that
primarily affects the lungs and infects over 2 billion
people worldwide. Although 90% of those infected have
latent, or inactive, tuberculosis infection (LTBI), one in
ten will become ill with active TB, and close to 2 mil-
lion will die from it each year. TB prevalence varies
dramatically from country to country (Figure 1) [3];
the prevalence of LTBIs in 2006 was 5% in the US
compared with 43% in Uganda and 55% in the Ivory
Coast [4]. An estimated 80% of the 8.8 million new
infections in 2005 were concentrated among 20 coun-
tries, and more than half of TB-related deaths in 2006
occurred in Asia [5]. In addition, although the per-
capita incidence of TB is stable or falling in all six
World Health Organization (WHO) regions, the num-
ber of cases and deaths continue to rise due to popu-
lation growth [5].
For many years, the WHO’s only LTBI testing op-
tion has been the TB skin test, yet its implementa-
tion is challenging because of its greatly diminished
sensitivity and specificity among certain populations
[6]. For example, skin test sensitivity is reduced in in-
dividuals with immunosuppressive diseases such as HIV
infection and among those taking immunosuppressant
medications, and specificity is diminished in people
who have had prior bacille Calmette-Guérin vaccine
and in those infected with non-TB environmental bacteria
[6-8].
New interferon–γ release assay (IGRA) tests have con-
sequently been developed for diagnosing LTBI and offer
improved operating characteristics over the standard
skin test. However, in considering the impact on testing
decisions of the interplay between prevalence, sensitivity,
and specificity as well as of other factors such as local
resources, healthcare systems, and treatment strategies,
the WHO has stated that IGRAs should not be used in
high-prevalence settings [9]. Recent research does indi-
cate, on the other hand, that IGRAs may be valuable
in low-prevalence settings, where the focus on LTBI
treatment renders highly specific tests the preferred
option [10]. What remains to be established is whether
decisions to use one IGRA over another in these
lower-prevalence settings may be conducted in such a
way as to optimize health outcomes and resource
utilization.
This paper thus focuses on the interplay between
sensitivity, specificity, and prevalence, independent of
prevalence-test performance interactions. Specifically,
we conducted two simple calculations – a hypothetical
generic example, and one with two IGRA tests for LTBI
screening – in settings of varying prevalence to quantify
the impact of changing sensitivity and specificity on testoutcomes. We assumed that sensitivity and specifici-
ty are independent of spectrum bias [11], and that
spectrum bias is not present when transitioning bet-
ween settings of varying prevalence. While this is
somewhat artificial and not representative of reality,
this simplifying assumption is made for purposes of
demonstration.
Methods
We estimated the number of true- and false-positive
results that would occur when varying prevalence and
test sensitivity and specificity. Inputs for the generic ex-
ample were hypothetical and for demonstration pur-
poses only, and those for the LTBI example were based
on published reports and literature.
Generic example
In the generic example, we predicted the number of
true-positive and false-negative results that would occur
with varying levels of test sensitivity and specificity, ap-
plied in four scenarios defined by disease prevalence
rates of 20%, 40%, 60%, and 80%. Among a hypothetical
cohort of 1,000 tested individuals, we calculated true-
positive test results with test sensitivity at 50%, 60%,
70%, and 80% and false-negative results with specificity
at 90%, 95%, 98%, and 99% (Tables 2 and 3).
Results were calculated as:
True Positive ¼ Sensitivity  Prevalence  N
False Negative ¼ ð1 SpecificityÞ  ð1 PrevalenceÞ  N
where N = 1,000 individuals.
LTBI testing example
We compared the consequences of implementing two
IGRA tests – QuantiFERONW-TB Gold In-Tube
(QFT-IT) and T-SPOTW.TB (T-Spot) – in settings of
varying LTBI prevalence by applying the sensitivity
and specificity of these tests to the generic example.
Table 3 False-positive resultsa in settings of varying
prevalence and tests of varying specificity
Disease prevalence rate Number of false-positive results
Specificity
90 % 95% 98% 99%
20% 80 40 16 8
40% 60 30 12 6
60% 40 20 8 4
80% 20 10 4 2
a Predicted numbers based on a hypothetical population of 1,000 tested
individuals.
Table 4 True- and false-positive resultsa when changing















United States 4.70% 329 12,389 37.7
Mexico 28.82% 2,018 9,253 4.6
Brazil 38.74% 2,712 7,964 2.9
Thailand 46.74% 3,272 6,924 2.1
Ivory Coast 54.62% 3,823 5,900 1.5
LTBI, latent tuberculosis infection; QFT-IT, QuantiFERON-TB Gold In-Tube;
T-Spot, T-SPOT.TB.
a Based on a hypothetical population of 100,000 tested individuals.
b Source: World Health Organization Global TB Database [4].
c Sensitivity estimates: QFT-IT 81%, T-Spot 88%; specificity estimates: QFT-IT
99%, T-Spot 86%.
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analysis to determine each test’s sensitivity and specifi-
city as [12]:
Sensitivity : QFT  IT ¼ 81%;T  Spot ¼ 88%
Specificity : QFT  IT ¼ 99%;T  Spot ¼ 86%
These estimates represent results from 19 pooled
QFT-IT studies and 17 pooled T-Spot studies for sen-
sitivity as well as from five pooled QFT-IT studies
and three pooled T-Spot studies for specificity. For all
T-Spot analyses, a positive test threshold of ≥6 spots
was used. Studies were published between 2006 and
2009 and included both developed and developing
countries. Using these estimates in our calculations,
switching from QFT-IT to T-Spot involves a 7% in-
crease in test sensitivity and a 13% decrease in
specificity.
The sensitivity and specificity differences between
QFT-IT and T-Spot are primarily due to manufacturers’
applied positive test thresholds for each test [7,10,12,13].
In addition, such estimates of test operating characteris-
tics are in fact highly population-dependent and vary
with factors such as age, geographic region, exposure to
other non-TB bacteria, stage and history of disease, and
immunosuppression. However, we considered for this
worked example fixed estimates of sensitivity and speci-
ficity, assuming that they remained stable within each
country, and we used data from test manufacturers to
ascertain that the positive test thresholds were equiva-
lent for each test across countries. We therefore
assumed in the calculations that prevalence was the only
difference between settings [12,13].
We evaluated results when using QFT-IT and T-Spot
in five countries chosen to represent a range of LTBI
prevalence estimates from the WHO [4]: United States
(5%), Mexico (29%), Brazil (39%), Thailand (47%), and
Ivory Coast (55%). All calculations were developed and
analyzed using ExcelW 2008 (©2007 Microsoft Corporation,
Redmond, WA).Results
Table 2 demonstrates how varying both the sensitivity
and prevalence affects the number of true positives.
Similarly, Table 3 shows how changes in the specificity
and prevalence affect the number of false positives.
Table 2 shows that increasing sensitivity increased the
number of true-positive results and that the absolute im-
pact was greater in high-prevalence settings: every 10%
increase in sensitivity produced 20 new true positives
per thousand when prevalence was 20% but 80 new true
positives when prevalence was 80%. On the other hand,
Table 3 shows that the impact of specificity on false
positives was greatest in the low-prevalence situation:
compared with a “perfect” test, a 10% decrease in speci-
ficity produced 80 new false positives at a prevalence of
20% and 20 new false positives at a prevalence of 80%.
Table 4 shows the predicted number of true- and
false-positive results and the ratio of false to true posi-
tives when switching from QFT-IT to T-Spot for LTBI
screening in five countries with varying prevalences.
When T-Spot (with a 7% greater sensitivity and 13%
lower specificity than QFT-IT) was used, our results pre-
dicted that countries with a lower prevalence would have
to pay a “price” of accepting more false positives for each
true positive diagnosis than would countries with a
higher prevalence. In the United States – with a 4.7%
LTBI prevalence – switching tests would result in ap-
proximately 38 people receiving false-positive findings
for each new true-positive diagnosis. On the other hand,
when prevalence is approximately six times greater (at
28.8% in Mexico), the number of false-positive results
per new true-positive diagnosis would decrease more
than eight-fold to 4.6. With increasing prevalence, this
false-positive to true-positive rate would continue to de-
cline to 2.9:1 in Brazil, 2.1:1 in Thailand, and 1.5:1 in the
Ivory Coast (with 38.7%, 46.7%, and 54.6% prevalence,
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estimated here, when prevalence increased over 11-fold
from 4.7% in the United States to 54.6% in Ivory Coast,
the false- to true-positive ratio decreased more than 20-
fold from 37.7 to 1.5.
Discussion
Our examples show that in addition to other factors,
policymakers and clinicians should consider real socio-
demographic factors such as prevalence when making
choices between tests and when setting positive test
thresholds in clinical practice as well as in policy guide-
lines. The interplay of sensitivity, specificity, and preva-
lence determines the balance of true and false results
associated with a given diagnostic test strategy, and all
three factors should be explicitly incorporated in evalu-
ating testing programs. With any given test, as disease
prevalence varies, the trade-off between the number of
false-positive and false-negative results will vary, resul-
ting in significant variations of health and economic con-
sequences across settings.
Other investigators have considered the importance of
incorporating prevalence in analyses of diagnostic tests.
Sackett and colleagues demonstrated early on that for
any given sensitivity and specificity the false-to-true
positive ratio will decrease and the positive predictive
value will increase with increasing prevalence [14]. It is
also well acknowledged that sensitivity and specificity
would likely change with varying prevalence, although
this may be a manifestation of changing patient
spectrum, with prevalence playing a secondary role [11].
The incorporation of prevalence along with sensitivity
and specificity has further been described in conducting
meta-analyses of diagnostic tests [15]. In addition, the
issue of pre-test probability has been considered particu-
larly relevant when using tests with an implicit or sub-
jective threshold, where clinicians may move their
subjective threshold in response to the perception of
increased prevalence [16,17].
In the current analysis, we used screening for LTBI to
demonstrate the importance of considering disease
prevalence when evaluating such trade-offs in testing
strategy decisions. We chose TB as an example because
of its growing worldwide importance, its variations in
prevalence (Figure 1), its diagnostic issues such as
comorbidities and latent-versus-active disease, and the
critical role of health systems and resources in determin-
ing optimal screening and treatment programs [3,4]. Al-
though early detection and effective screening are
critical to TB treatment and prevention, improvements
in detection have recently slowed, with close to 40% of
infections worldwide still not being properly detected or
treated [5]. This slowing is in part due to the lower sen-
sitivity and specificity of the standard TB skin testamong certain populations [6-8] as well as the chal-
lenges in determining appropriate testing strategies in
settings of highly varied levels of disease prevalence and
resource constraints.
For example, in lower-burdened and higher-resourced
countries such as the US, TB-control strategies target
high-specificity LTBI screening and treatment to prevent
later conversion to active TB. Such a strategy, however,
is less common in higher-prevalence settings where
resources are more often allocated towards treating
those with active infection and especially in poorer set-
tings where treatment costs may be more than double a
household’s monthly income [18]. So although the intro-
duction of newer tests such as QFT-IT and T-Spot can
offer improved operating characteristics, improvements
in outcomes depend on the establishment of testing
strategies that are specific to each setting.
Thus, with the recent introduction of new tests for TB
and the publication of WHO and FDA guidelines
regarding their implementation, this analysis provides a
timely demonstration that highly specific IGRA tests
cause more harm and generate fewer benefits when used
in high-prevalence countries, where there would be too
many false negatives, too little treatment of diseased
individuals, and more future illness and disease spread.
In addition to confirming the WHO’s recommendations
that IGRAs not be used in developing countries, our
analysis also is useful to show that in making LTBI test-
ing decisions within lower-prevalence developed coun-
tries, there may be benefits of using one IGRA test over
another, depending on prevalence. The lower the preva-
lence, the more specific the test should be.
Our analysis is not only useful for making decisions
between tests but also in determining setting-specific
positive test thresholds. With the FDA’s 2009 decision to
change the T-Spot cutoff for a positive result from six to
eight spots [19,20], it actively weighed the sensitivity-
specificity balance in the face of lower-prevalence TB in
the US. This decision recognized that changing the
threshold would decrease test sensitivity, yet it would in-
crease specificity and result in improved outcomes for
this setting. However, because of the inherent nature of
the test, it is possible that this changed threshold may
not increase specificity to the levels of the QFT-IT [10].
Therefore, if the revised T-Spot sensitivity and specificity
values were known and included in the current analysis,
the magnitude of differences in outcomes between the
two tests would clearly diminish; however; the degree of
decline is uncertain and is unlikely to be absolute. More
research is needed to clearly determine the specificity of
IGRAs in settings of varying prevalence, and in particu-
lar of the T-Spot assay with the revised US threshold.
Our TB example is a good demonstration of the issue
of determining appropriate diagnostic testing strategies
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throughout the world. Consider, for example, two coun-
tries: one developed, the other not. Healthcare in the
developed country is generally good, multi-drug resistant
TB is relatively rare, and TB prevalence is relatively low.
In the developing country, healthcare access is more
limited, resistant TB is more common, and TB preva-
lence is higher.
An LTBI test such as T-Spot that offers a significant
increase in sensitivity – compared with QFT-IT – at the
cost of a 13% decrease in specificity may be valued dif-
ferently in the two countries. The developed country
may find that the 7% increase in early case detection
benefits too few people to justify the high burden of false
positives. The developing country may find that with
higher disease prevalence, the greater increase in early
detection is worth the increased treatment of false-
positive cases, especially given the poorer access to med-
ical services. This is not to say that the trade-off is not
worthwhile in the developed country or that it is worth-
while in the developing country. Resources and local pri-
orities and values should determine that. Rather, one
should not expect the trade-off to be similar in different
areas; indeed, it may differ by orders of magnitude as
prevalence varies.
Despite this differential impact between settings, test-
ing decisions do not always consider specific populations
and disease characteristics, and like those for QFT-IT
and T-Spot, positive-result thresholds are usually set at a
global level by manufacturers and applied consistently
across countries [12,13]. Given that the prevalence of
many diseases varies worldwide, encouraging policy-
makers to explicitly incorporate disease prevalence in
their testing decisions and allowing them to choose
setting-specific thresholds – or to choose from a menu
of possible choices – could increase the value of a given
test by optimizing test performance and improving
health and economic outcomes.
Tuberculosis is a good example for demonstrating the
impact of prevalence in decisions regarding positive
thresholds and test strategies because of issues such as
the challenges of estimating accurate test operating char-
acteristics, the varying disease prevalence, and the differ-
ences between active and latent infection. Although such
issues apply when testing for any disease, they must be
taken into account when interpreting the implications of
our analysis. For example, the impact of incorrect LTBI
diagnoses can be particularly difficult to estimate be-
cause of low treatment compliance and the challenge of
estimating the impact of delayed diagnoses. This analysis
also ignores other issues involved in testing for the less-
prevalent active TB [6-8].
In addition, test sensitivity and specificity and the im-
pact of prevalence are not the only determinants of atest’s usefulness, and decisions regarding positive test
thresholds and test usefulness in different settings must
consider a multitude of factors. To name but a few: vari-
ation in estimates of test sensitivity and specificity (e.g.,
as determined by factors such as study methodology);
balance of risks and benefits; reason for testing (screen-
ing or diagnosis); population-specific geography and
demographics; patient preference; and patient values for
different outcomes (e.g., associated with culture). Testing
programs may maximize benefit, minimize risk, and suc-
cessfully prevent and treat disease only when all such
factors are considered. Although the examples discussed
herein come from only one disease (TB), this should not
be considered a limitation of the study. Rather, this ana-
lysis demonstrates an epidemiologic principle that holds
true for any disease, even though the magnitude of effect
will vary from one disease to another.Conclusions
No matter what the sensitivity and specificity of a test
are, the prevalence determines the absolute numbers of
missed cases and over-treated non-cases. Authors of pri-
mary studies and systematic reviews of diagnostic accur-
acy could be more aware of this issue. Testing policies
should specifically address each setting’s disease and
population characteristics, and sensitivity and specificity
should be evaluated as a function of all relevant criteria
that include disease prevalence and positive thresholds.
Future research should evaluate the benefit-risk trade-
offs involved in incorporating new and standard tests, at
varying positive test thresholds, and in high- and low-
prevalence settings. Evaluating the trade-offs between
true and false positives can aid decision makers in decid-
ing between tests of varying sensitivity and specificity, in
determining the optimal threshold for a positive test,
and in ultimately optimizing disease-related outcomes in
different global settings.Competing interests
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